Diagnostics News and Research

RSS

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

BioImagene collaborates with ten new academic medical centers to develop digital pathology solutions

BioImagene, Inc., the leading provider of innovative digital pathology solutions has added ten new academic medical centers to its roster of collaborators during the last quarter. Many of these collaborators have been named "America's Best Hospitals 2010-2011: The Honor Roll" by U.S. News and World Report.

28 Jul 2010

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

Akonni Biosystems a molecular diagnostics company focused on developing and manufacturing rapid, high multiplex solutions for infectious disease testing, today announced receipt of a $435K grant from the National Institutes of Biomedical Imaging and Bioengineering at the National Institutes of Health. The award will enable Akonni to accelerate development of its hands-free, sample-to-answer system for identifying a broader range of multi-drug resistant strains of Mycobacterium tuberculosis.

28 Jul 2010

GE Healthcare completes new $15 million medical technology manufacturing facility in Cardiff, Wales

Life sciences giant GE Healthcare has opened a $15 million medical technology manufacturing facility in Cardiff, Wales. The new facility is based at the 30-acre Maynard Centre, where the company already employs over 400 people.

28 Jul 2010

Thermo Fisher Scientific highlights products, services for clinical research and specialty diagnostics at AACC 2010

Thermo Fisher Scientific Inc., the world leader in serving science, will highlight its innovative offering of products and services for clinical research and specialty diagnostics during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo held in Anaheim, California, July 25 - 29, 2010.

From Thermo Fisher Scientific Inc. 27 Jul 2010

BK Medical appointed as sole agent for AMD's Prostate HistoScanning in UK

Advanced Medical Diagnostics SA, a privately held company committed to providing innovative computer-aided solutions (HistoScanning™) that can improve the diagnostic interpretation of ultrasound scans, today announced that it has appointed BK Medical UK Ltd as sole agent for Prostate HistoScanning™ in the UK.

27 Jul 2010

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

Australian medical devices market to grow at 9% CAGR in 2009-2012

The consequences as a result of the major Australian healthcare reform plan will impact the outlook of the medical devices industry, and possibly precipitate a series of rapid changes for the market.

27 Jul 2010

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information.

From Roche Sequencing and Life Science 27 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

Vermillion, Inc., a molecular diagnostics company, today announced that it is relocating its corporate headquarters from Fremont, California to Austin, Texas. Vermillion has executed a two-year lease for a new principal place of business at 12117 Bee Cave Road, Building Two, Suite 100, Austin, TX 78731. Vermillion will continue to operate research and development, regulatory and quality operations in California. All other functions will be conducted at the Austin offices.

23 Jul 2010

IDEXX Laboratories second-quarter 2010 revenues increase 6% to $281.5 million

IDEXX Laboratories, Inc., today reported that revenues for the second quarter of 2010 increased 6% to $281.5 million, from $265.7 million for the second quarter of 2009. Organic revenue growth, as defined below, was 5%. Earnings per diluted share for the quarter ended June 30, 2010 increased 13% to $0.62, compared to $0.55 for the same period in the prior year.

23 Jul 2010

Choice between late-term abortion or keeping an unhealthy foetus

Most pregnant women whose foetus is proven to have a genetic abnormality choose to have an abortion, but reaching that decision is a painful, exhausting process for most of them. "The women's doubt, pain and sorrow make abortion more moral - in the eyes of society as well as her own," says Sølvi Marie Risøy, a researcher at the Stein Rokkan Centre for Social Studies, University of Bergen.

23 Jul 2010

New era of scientific innovation to drive novel ways of treating, preventing HIV

The unwillingness of the global AIDS community to accept the status quo is fuelling a new era of scientific innovation to drive novel ways of treating and preventing HIV, organizers of the XVIII International AIDS Conference taking place in Vienna, Austria said today. And, with millions of lives dependent on expanding access to antiretroviral treatment to all those clinically in need, researchers and clinicians are partnering in new ways to find the most effective and efficient methods to deliver treatment and strengthen health systems.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

Quest Diagnostics income from continuing operations increases to $195 million in second-quarter 2010

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.

From Quest Diagnostics 21 Jul 2010

Diagnostics News and Research

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

BioImagene collaborates with ten new academic medical centers to develop digital pathology solutions

NIH awards Akonni $435K to develop point-of-care diagnostics for multi-drug resistant strains of MTB

GE Healthcare completes new $15 million medical technology manufacturing facility in Cardiff, Wales

Thermo Fisher Scientific highlights products, services for clinical research and specialty diagnostics at AACC 2010

BK Medical appointed as sole agent for AMD's Prostate HistoScanning in UK

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

Abbot's innovative solutions to be highlighted at AACC

Australian medical devices market to grow at 9% CAGR in 2009-2012

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Axela acquires Xceed Molecular

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Vermillion to complete relocation of corporate offices to Austin, Texas by September 2010

IDEXX Laboratories second-quarter 2010 revenues increase 6% to $281.5 million

Choice between late-term abortion or keeping an unhealthy foetus

New era of scientific innovation to drive novel ways of treating, preventing HIV

Affymetrix second-quarter total revenue decreases to $71.7 million

Genzyme second-quarter revenue decreases to $1.08 billion

Quest Diagnostics income from continuing operations increases to $195 million in second-quarter 2010

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News